한글목차

자궁내막증 유병률 증가는 치료 시장 확대를 촉진하는 주요 요인입니다. 자궁내막증 진단을 받는 인구가 증가함에 따라 효과적인 치료 옵션에 대한 수요는 지속적으로 증가하고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 2024년 자궁내막증은 전 세계 가임기 여성과 여아의 약 10%(1억 9,000만 명)에게 영향을 미칠 것으로 예상하고 있습니다.

많은 여성들이 심한 통증, 불임 및 기타 합병증에 직면하고 있으며, 다양한 증상을 해결하고 전반적인 삶의 질을 향상시킬 수 있는 치료의 필요성이 강조되고 있습니다. 마찬가지로, 2023년 European Journal of Medical and Health Sciences의 보고에 따르면, 자궁내막증은 전 세계적으로 2억 4,700만 명, 인도에서는 4,200만 명의 여성이 앓고 있는 것으로 추정됩니다. 더 나은 치료 옵션에 대한 요구가 증가함에 따라 제약 및 수술적 솔루션의 혁신이 가속화되고 있습니다. 자궁내막증에 대한 인식이 높아지고 보다 효과적인 치료법이 등장함에 따라 자궁내막증 치료 시장은 지속적으로 성장할 것으로 예상됩니다.

새로운 자궁내막증 치료법 개발에 따른 높은 개발 비용이 치료 시장의 성장을 저해할 것으로 예상됩니다. 자궁내막증에 대한 효과적인 치료법을 개발하기 위해서는 광범위한 조사, 임상시험, 규제 당국의 승인이 필요하며, 이 모든 과정에 많은 비용과 시간이 소요됩니다. 특히 자궁내막증이라는 질병의 복잡한 특성과 보편적으로 효과적인 치료법 개발이라는 과제를 고려할 때, 이러한 높은 비용은 신약 및 의료기기 개발에 투자하고자 하는 제약회사의 수를 제한할 수 있습니다.

세계의 자궁내막증 치료제 시장에 대해 조사했으며, 시장 개요와 함께 치료 유형별/약물 유형별/투여 경로별/유통 채널별/지역별 동향, 경쟁 구도, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 조사 방법과 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 영향 분석

제5장 전략적 인사이트와 업계 전망

• 시장 리더와 선구자
• CXO의 견해
• 최신 개발과 Break through
• 사례 연구/진행중인 조사
• 규제와 상환 상황
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 권장 전략
• 시나리오 분석 : 베스트 케이스, 기본 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• 주요 업계 리더

제6장 치료 유형별

• 진통제
• 호르몬 요법

제7장 약제 클래스별

• NSAID
• 경구 피임약
• 고나드트로핀 방출 호르몬
• 기타

제8장 투여 경로별

• 경구
• 주사
• 기타

제9장 유통 채널별

• 병원 약국
• 소매 약국
• E-Commerce
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 남미
  • 브라질
  • 아르헨티나
  • 기타
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타
• 중동 및 아프리카

제11장 경쟁 구도

제12장 기업 개요

• Bayer AG
• AbbVie, Inc
• AstraZeneca
• Gedeon Richter Plc.
• TORRENT PHARMACEUTICALS LTD.
• Sanofi SA
• Gynogen
• Weefsel Pharma

제13장 부록

영문목차

The global Endometriosis Treatment market reached US$ 1.59 billion in 2024 and is expected to reach US$ 3.91 billion by 2033, growing at a CAGR of 10.62% during the forecast period 2025-2033.

Endometriosis is a chronic condition that causes tissue, similar to the lining inside the uterus, to grow outside of it. This tissue commonly develops on the ovaries, fallopian tubes, and the outer walls of the uterus. As the tissue responds to hormonal changes, it can result in severe pain, particularly during menstruation, as well as other symptoms such as pelvic discomfort, pain during sex, heavy bleeding, and infertility.

Treatment for endometriosis focuses on alleviating pain, slowing the growth of the endometrial tissue, and improving fertility if needed. Common approaches include pain relief through nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies like birth control pills, progestins, and GnRH agonists, which help regulate hormone levels and reduce the growth of endometrial tissue. These treatments aim to manage the symptoms and offer relief, though more severe cases may require additional interventions.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Endometriosis

The growing prevalence of endometriosis is a major factor driving the expansion of the treatment market. As more people are diagnosed, the demand for effective treatment options continues to grow. For instance, according to the World Health Organization in 2024, Endometriosis is affecting an estimated 10% (190 million) of women and girls of reproductive age globally

Many women face severe pain, infertility, and other complications, which underscores the need for treatments that can address the wide range of symptoms and improve overall quality of life. Similarly, according to the report by the European Journal of Medical and Health Sciences in 2023, it is stated that endometriosis affects ~247 million women globally and ~42 million women in India. This growing need for better treatment options is spurring innovations in both pharmaceutical and surgical solutions. As awareness increases and more effective treatments emerge, the endometriosis treatment market is expected to keep growing in the coming years.

High developmental costs

The high developmental cost associated with creating new treatments for endometriosis is expected to hinder the growth of the treatment market. Developing effective therapies for endometriosis requires extensive research, clinical trials, and regulatory approvals, all of which are expensive and time-consuming. This high cost can limit the number of pharmaceutical companies willing to invest in the development of new drugs or medical devices, especially given the complex nature of the disease and the challenges in creating universally effective treatments.

Segment Analysis

The global endometriosis treatment market is segmented based on product type, application, end-user, and region.

Drug Class:

NSAIDs segment is expected to dominate the global endometriosis treatment market share

The NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) segment is expected to dominate the endometriosis treatment market. This is because they are frequently the first-line treatment for pain associated with endometriosis due to their ability to inhibit prostaglandin production and alleviate cramps.due to their widespread availability, cost-effectiveness, and effectiveness in managing pain.

Endometriosis commonly causes severe pain, especially during menstruation, and NSAIDs like ibuprofen and naproxen are often used as first-line treatments to provide pain relief. These drugs work by blocking the production of prostaglandins, which reduce inflammation and alleviate pain.

Geographical Analysis

North America is expected to hold a significant position in the global endometriosis treatment market share

North America is expected to hold a significant position in the global endometriosis treatment market due to several key factors. Additionally, there is growing awareness about endometriosis, which is driving higher rates of diagnosis and, consequently, the demand for treatment options. The region also benefits from major pharmaceutical companies developing and commercializing new therapies, ensuring that patients have access to cutting-edge treatments.

Furthermore, the increasing focus on women's health issues and initiatives to improve diagnosis and awareness of endometriosis have contributed to the region's dominant market share. Additionally, the strategic activities of market players, such as introducing new products, contribute to market growth in the region.

Research and innovation of advanced solutions are being rigorously made in the region, contributing to the region's market growth. For instance, in January 2025, Celmatix Therapeutics announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The therapeutic drug candidate, developed using the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM), aims to address a critical unmet need in first-line treatments for a range of women's health indications, starting with endometriosis and potentially extending to Polycystic Ovary Syndrome (PCOS) and ovarian aging.

Competitive Landscape

The major global players in the endometriosis treatment market include Bayer AG, Pfizer, Inc., AbbVie, Inc, AstraZeneca, Gedeon Richter Plc., TORRENT PHARMACEUTICALS LTD., Sanofi SA, Gynogen, and Weefsel Pharma among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Endometriosis Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Endometriosis
  • 4.1.2. Restraints
    • 4.1.2.1. High Developmental Costs
  • 4.1.3. Opportunity
• 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Pain Medication*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Hormone Therapy

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. NSAIDs*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oral Contraceptives
• 7.4. Gonadotropin-Releasing Hormone
• 7.5. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Injectable
• 8.4. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacy*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacy
• 9.4. e-Commerce
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Bayer AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. AbbVie, Inc
• 12.3. AstraZeneca
• 12.4. Gedeon Richter Plc.
• 12.5. TORRENT PHARMACEUTICALS LTD.
• 12.6. Sanofi SA
• 12.7. Gynogen
• 12.8. Weefsel Pharma
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us